XTLB (XTL Biopharmaceuticals) Revenue: $0.00 Mil (TTM As of Dec. 2025)


XTLB XTL Biopharmaceuticals Ltd XTLB
26 GF Score
Price $2.91
! 4 Warning Signs
View Full Analysis

What is XTL Biopharmaceuticals Revenue?

XTL Biopharmaceuticals XTLB +0.69% 26 Revenue is $0.00 Mil as of Dec. 2025. GuruFocus rates XTLB with a GF Score™ of 26/100. The stock has 4 warning signs investors should review.

XTL Biopharmaceuticals's revenue for the six months ended in Dec. 2025 was $-0.52 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil. XTL Biopharmaceuticals's Revenue per Share for the six months ended in Dec. 2025 was $-0.23. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, XTL Biopharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 119.10% per year. The lowest was 16.40% per year. And the median was 67.75% per year.


XTL Biopharmaceuticals  (NAS:XTLB) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


XTL Biopharmaceuticals Revenue Related Terms


XTL Biopharmaceuticals Revenue Historical Data

* Premium members only.

The historical data trend for XTL Biopharmaceuticals's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XTL Biopharmaceuticals Revenue Chart

XTL Biopharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

XTL Biopharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.52 -0.52

XTLB vs VRTX, REGN, ALNY: Revenue Comparison

For the Biotechnology subindustry, XTL Biopharmaceuticals's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XTL Biopharmaceuticals Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XTL Biopharmaceuticals's Revenue distribution charts can be found below:

* The bar in red indicates where XTL Biopharmaceuticals's Revenue falls into.


XTLB
26GF Score
XTL Biopharmaceuticals Ltd XTLB
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

XTL Biopharmaceuticals Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of $0.00 Mil mean?
XTL Biopharmaceuticals (XTLB) has a Revenue of $0.00 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on XTL Biopharmaceuticals and its competitors.
Is XTL Biopharmaceuticals' Revenue too high?
XTL Biopharmaceuticals' current Revenue is $0.00 Mil. Overall, XTL Biopharmaceuticals has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does XTL Biopharmaceuticals' Revenue compare to VRTX and REGN?
XTL Biopharmaceuticals' Revenue of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on XTL Biopharmaceuticals and its competitors. XTL Biopharmaceuticals's current Revenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XTL Biopharmaceuticals stock overvalued right now?
XTL Biopharmaceuticals (XTLB) has a current Revenue of $0.00 Mil. The current Revenue is $0.00 Mil. XTL Biopharmaceuticals' overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For XTL Biopharmaceuticals (XTLB), the current Revenue is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

XTL Biopharmaceuticals Business Description

Other Exchanges XTLB:IsraelHHB0:Germany
Address 26 Ben-Gurion Street, Ramat Gan, ISR, 5112001
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
26GF Score

Get the complete analysis for XTLB

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.91
Price